|Bid||100.00 x 1000|
|Ask||104.83 x 900|
|Day's Range||101.84 - 108.02|
|52 Week Range||35.25 - 110.74|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||118.67|
Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer. The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient's tumor profile and effectively recommend targeted therapies or clinical trials.
Here are the top stocks that you should have invested in.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.